LU90769I2 - Capecitabine et ses d-riv-es pharmaceutiquement acceptables (xeloda) - Google Patents

Capecitabine et ses d-riv-es pharmaceutiquement acceptables (xeloda)

Info

Publication number: LU90769I2
Authority: LU; Luxembourg
Prior art keywords: xeloda; capecitabine; pharmaceutically acceptable; acceptable derivatives; derivatives
Prior art date: 1987-11-17

Application number

LU90769C

Other languages

English (en)

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-11-17

Filing date

2001-05-02

Publication date

2001-07-02

2001-05-02 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2001-07-02 Publication of LU90769I2 publication Critical patent/LU90769I2/fr

Links

GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 title 2
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 title 1
229960004117 capecitabine Drugs 0.000 title 1
229940053867 xeloda Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

LU90769C 1987-11-17 2001-05-02 Capecitabine et ses d-riv-es pharmaceutiquement acceptables (xeloda) LU90769I2 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP87116926		1987-11-17

Publications (1)

Publication Number	Publication Date
LU90769I2 true LU90769I2 (fr)	2001-07-02

Family

ID=8197450

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU90769C LU90769I2 (fr)	1987-11-17	2001-05-02	Capecitabine et ses d-riv-es pharmaceutiquement acceptables (xeloda)

Country Status (34)

Country	Link
US (1)	US4966891A (fr)
EP (1)	EP0316704B1 (fr)
JP (1)	JPH0678350B2 (fr)
KR (1)	KR970000241B1 (fr)
CN (1)	CN1022688C (fr)
AR (1)	AR247217A1 (fr)
AT (1)	ATE124951T1 (fr)
AU (1)	AU619220B2 (fr)
CA (1)	CA1327358C (fr)
CS (1)	CS274486B2 (fr)
DE (2)	DE10199027I2 (fr)
DK (1)	DK170893B1 (fr)
DZ (1)	DZ1270A1 (fr)
ES (1)	ES2074429T3 (fr)
FI (1)	FI89804C (fr)
GR (1)	GR3017686T3 (fr)
HU (1)	HU199866B (fr)
IE (1)	IE883430L (fr)
IL (1)	IL88363A0 (fr)
IS (1)	IS1895B (fr)
LT (1)	LT2185B (fr)
LU (1)	LU90769I2 (fr)
LV (1)	LV5624A3 (fr)
MC (1)	MC1992A1 (fr)
MX (1)	MX173347B (fr)
NL (1)	NL300045I2 (fr)
NO (2)	NO171167C (fr)
NZ (1)	NZ226923A (fr)
PH (1)	PH25641A (fr)
PT (1)	PT89009B (fr)
SU (1)	SU1736342A3 (fr)
UA (1)	UA19333A (fr)
YU (1)	YU47122B (fr)
ZA (1)	ZA888428B (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6258360B1 (en) *	1989-05-04	2001-07-10	Igen International, Inc.	Prodrugs activated by targeted catalytic proteins
US5527782A (en) *	1990-03-13	1996-06-18	Acic (Canada) Inc.	5-halo-2,3'-O-cyclocytidines
AU671491B2 (en) *	1992-12-18	1996-08-29	F. Hoffmann-La Roche Ag	N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
TW254946B (fr) *	1992-12-18	1995-08-21	Hoffmann La Roche
US5476932A (en) *	1994-08-26	1995-12-19	Hoffmann-La Roche Inc.	Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
IT1291983B1 (it) *	1997-05-23	1999-01-25	Pro Bio Sint Srl	Prodcedimento per la preparazione di un derivato della desossiuridina
NZ330360A (en) *	1997-06-02	1999-03-29	Hoffmann La Roche	5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
EP0882734B1 (fr) *	1997-06-02	2009-08-26	F. Hoffmann-La Roche Ag	Dérivés de 5'-déoxy-cytidine
US6005098A (en) *	1998-02-06	1999-12-21	Hoffmann-La Roche Inc.	5'deoxycytidine derivatives
US20080113025A1 (en) *	1998-11-02	2008-05-15	Elan Pharma International Limited	Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20010051348A1 (en) *	2000-01-28	2001-12-13	Lee Chee Wee	Novel ligands and methods for preparing same
SE0102764D0 (sv)	2001-08-17	2001-08-17	Astrazeneca Ab	Compounds
EP2316468A1 (fr)	2002-02-22	2011-05-04	Shire LLC	Système de distribution et méthodes de protection et d'administration de dextroamphetamine
US6774758B2 (en) *	2002-09-11	2004-08-10	Kalyan P. Gokhale	Low harmonic rectifier circuit
GB0226930D0 (en)	2002-11-19	2002-12-24	Astrazeneca Ab	Chemical compounds
CA2525973A1 (fr) *	2003-05-20	2004-12-09	Aronex Pharmaceuticals, Inc.	Chimiotherapie combinee comprenant capecitabine et un complexe a base de platine liposomique
DK1706414T3 (da) *	2003-12-22	2008-10-13	Hoffmann La Roche	Fremgangsmåde til fluorcytidinderivater
JP2007523905A (ja) *	2004-02-18	2007-08-23	アストラゼネカアクチボラグ	化合物
EP2048137A1 (fr) *	2004-02-18	2009-04-15	AstraZeneca AB	Dérivés de la benzamide et leur utilisation comme activateurs de la glucokinase.
CN100383128C (zh) *	2004-02-23	2008-04-23	上海迪赛诺医药发展有限公司	N4－氧羰基胞嘧啶衍生物及制备方法与应用
TW200600086A (en)	2004-06-05	2006-01-01	Astrazeneca Ab	Chemical compound
KR101061850B1 (ko)	2004-09-08	2011-09-02	삼성전자주식회사	박막 트랜지스터 표시판 및 그 제조방법
GB0421294D0 (en) *	2004-09-24	2004-10-27	Angiogene Pharm Ltd	Bioreductively-activated prodrugs
GB0423043D0 (en) *	2004-10-16	2004-11-17	Astrazeneca Ab	Compounds
BRPI0516595A (pt)	2004-10-16	2008-09-23	Astrazeneca Ab	processo para fabricar um composto, e, composto
NZ556673A (en)	2005-02-03	2010-03-26	Gen Hospital Corp	Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
NO322682B1 (no) *	2005-03-18	2006-11-27	Clavis Pharma Asa	Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
AU2006228581A1 (en) *	2005-04-01	2006-10-05	F. Hoffmann-La Roche Ag	Method for administration of capecitabine
EP1891069A1 (fr) *	2005-05-24	2008-02-27	AstraZeneca AB	Derives d'imidazol[4,5b]pyridine/pyrazine et purine substitues en 2-phenyl en tant que modulateurs de la glucokinase
TW200714597A (en)	2005-05-27	2007-04-16	Astrazeneca Ab	Chemical compounds
KR20110084339A (ko)	2005-07-09	2011-07-21	아스트라제네카 아베	당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
US20110053910A1 (en) *	2005-07-09	2011-03-03	Mckerrecher Darren	2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
EP2027113A1 (fr) *	2005-07-09	2009-02-25	AstraZeneca AB	Dérivés d'hétéroaryl benzamide utilisés en tant qu'activateurs de la glk dans le traitement du diabète
CN100569790C (zh) *	2005-07-15	2009-12-16	上海奥锐特国际贸易有限公司	合成n4-酰基-5＇-脱氧-5-氟胞苷衍生物的方法
ATE546148T1 (de) *	2005-07-21	2012-03-15	Nuvo Res Ag	Stabilisierte chlorit-lösungen in kombination mit fluorpyrimidinen zur krebsbehandlung
US9202182B2 (en) *	2005-08-11	2015-12-01	International Business Machines Corporation	Method and system for analyzing business architecture
EP3488866A1 (fr)	2005-11-04	2019-05-29	Wyeth LLC	Combinaisons antinéoplasiques avec inhibiteur de mtor, d'herceptine et/ou hki-272
TW200738621A (en)	2005-11-28	2007-10-16	Astrazeneca Ab	Chemical process
US20080085310A1 (en) *	2006-10-06	2008-04-10	Maria Oksana Bachynsky	Capecitabine rapidly disintegrating tablets
TW200825063A (en)	2006-10-23	2008-06-16	Astrazeneca Ab	Chemical compounds
TW200825060A (en)	2006-10-26	2008-06-16	Astrazeneca Ab	Chemical compounds
CN100425617C (zh) *	2006-10-31	2008-10-15	浙江海正药业股份有限公司	一种含氟嘧啶类化合物烷氧羰酰化的方法
MX2009006729A (es)	2006-12-21	2009-08-07	Astrazeneca Ab	Nuevo compuesto cristalino util como activador de glk.
ITMI20070435A1 (it)	2007-03-05	2008-09-06	Innovate Biotechnology Srl	2',3'-di-o-acil-5-fluoronucleosidi
US20100130734A1 (en) *	2007-04-20	2010-05-27	Dr. Reddy's Laboratories Ltd.	Process for preparing capecitabine
WO2008145403A1 (fr) *	2007-06-01	2008-12-04	Synthon B.V.	Procédés se rapportant à la fabrication de la capécitabine
US8741858B2 (en)	2007-09-21	2014-06-03	Zhongxu Ren	Oligomer-nucleoside phosphate conjugates
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR20090122955A (ko) *	2008-01-03	2009-12-01	플러스 케미칼스, 에스.에이.	카페시타빈의 제조 방법
ES2531322T3 (es)	2008-06-17	2015-03-13	Wyeth Llc	Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
MX2011001333A (es)	2008-08-04	2011-03-15	Astrazeneca Ab	Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad.
EP3175853B1 (fr)	2008-08-04	2023-11-01	Wyeth LLC	Combinaisons antinéoplasiques contenant du neratinib et de la capécitabine
WO2010065586A2 (fr) *	2008-12-02	2010-06-10	Dr. Reddy's Laboratories Ltd.	Préparation de capécitabine
EP2393472B1 (fr) *	2008-12-05	2019-06-05	NanoMed Holdings Pty Ltd	Promédicaments amphiphiles
CN101787066B (zh) *	2009-01-23	2013-07-31	高峰	阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
GB0902406D0 (en)	2009-02-13	2009-04-01	Astrazeneca Ab	Crystalline polymorphic form
GB0902434D0 (en)	2009-02-13	2009-04-01	Astrazeneca Ab	Chemical process
PT3000467T (pt)	2009-04-06	2023-03-30	Wyeth Llc	Regime de tratamento utilizando neratinib para o cancro de mama
AR076220A1 (es)	2009-04-09	2011-05-26	Astrazeneca Ab	Derivados de pirazol [4,5 - e] pirimidina
WO2010116176A1 (fr) *	2009-04-09	2010-10-14	Astrazeneca Ab	Dérivé de pyrazolo [4, 5-e] pyrimidine et son utilisation pour traiter le diabète et l'obésité
CN101875680B (zh) *	2009-04-28	2012-07-25	上海信旗医药科技有限公司	一种核苷类化合物及其制备方法和应用
CN102858791A (zh) *	2009-07-23	2013-01-02	台湾神隆股份有限公司	制备氟胞苷衍生物的方法
EP3117709B1 (fr)	2010-03-12	2018-08-01	Genzyme Corporation	Therapie combinee pour le traitement du cancer du sein
WO2013151664A1 (fr)	2012-04-02	2013-10-10	modeRNA Therapeutics	Polynucléotides modifiés pour la production de protéines
CN104411338A (zh)	2012-04-02	2015-03-11	现代治疗公司	用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
WO2014048939A1 (fr)	2012-09-26	2014-04-03	F. Hoffmann-La Roche Ag	Composés d'éther cyclique-pyrazol-4-yl-hétérocyclyl-carboxamide et procédés d'utilisation
US9447137B2 (en)	2012-11-07	2016-09-20	Nucorion Pharmaceuticals, Inc.	Substituted gemcitabine aryl amide analogs
WO2014145207A1 (fr) *	2013-03-15	2014-09-18	Ohio State Innovation Foundation	Analogues d'amide bicyclique de gemcitabine substitués et méthodes de traitement à l'aide de ceux-ci
EP2971033B8 (fr)	2013-03-15	2019-07-10	ModernaTX, Inc.	Procédés de fabrication pour la production de transcrits d'arn
WO2015034925A1 (fr)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Polynucléotides circulaires
CA2923029A1 (fr)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Polynucleotides chimeriques
CN103450301B (zh) *	2013-09-09	2015-09-09	南通大学	法尼基硫代水杨酸-核苷缀合物、其制备方法及其医药用途
KR20160067219A (ko)	2013-10-03	2016-06-13	모더나 세라퓨틱스, 인코포레이티드	저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
CN109414438A (zh) *	2016-06-28	2019-03-01	塞尔利克斯生物私人有限公司	用于治疗癌症的组合物和方法
US11584733B2 (en)	2017-01-09	2023-02-21	Shuttle Pharmaceuticals, Inc.	Selective histone deacetylase inhibitors for the treatment of human disease
US11034667B2 (en)	2017-01-09	2021-06-15	Shuttle Pharmaceuticals, Inc.	Selective histone deacetylase inhibitors for the treatment of human disease
EP3618837A4 (fr)	2017-04-26	2020-11-04	Thomas I. Kalman	Dérivés de nucléoside multicibles
US10435429B2 (en)	2017-10-03	2019-10-08	Nucorion Pharmaceuticals, Inc.	5-fluorouridine monophosphate cyclic triester compounds
WO2019139921A1 (fr)	2018-01-09	2019-07-18	Shuttle Pharmaceuticals, Inc.	Inhibiteurs sélectifs d'histone déacétylase pour le traitement d'une maladie humaine
AU2019207626B2 (en)	2018-01-10	2023-10-05	Nucorion Pharmaceuticals, Inc.	Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en)	2018-01-19	2022-08-30	Nucorion Pharmaceuticals, Inc.	5-fluorouracil compounds
CN111801339B (zh) *	2018-01-19	2025-06-24	纽科利制药公司	5-氟尿嘧啶化合物
SG11202100411TA (en) *	2018-08-03	2021-02-25	Cellix Bio Private Ltd	Compositions and methods for the treatment of cancer
CN109651467A (zh) *	2019-01-15	2019-04-19	齐鲁天和惠世制药有限公司	一种卡培他滨杂质及其制备方法
WO2021011692A1 (fr)	2019-07-17	2021-01-21	Nucorion Pharmaceuticals, Inc.	Composés désoxyribonucléotidiques cycliques
WO2021216431A1 (fr)	2020-04-21	2021-10-28	Ligand Pharmaceuticals, Inc.	Composés de benzyloxy phosph(on)ate
EP4143199B1 (fr)	2020-04-21	2025-11-19	Ligand Pharmaceuticals, Inc.	Composés de promédicaments nucléotidiques
JP2023535225A (ja)	2020-07-24	2023-08-16	ストランドセラピューティクスインコーポレイテッド	改変ヌクレオチドを含む脂質ナノ粒子
KR20230129479A (ko)	2021-01-08	2023-09-08	스트랜드 세러퓨틱스 인코포레이티드	발현 구성체 및 이의 용도
AU2023262576A1 (en)	2022-04-26	2024-10-10	Strand Therapeutics Inc.	Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
WO2025193628A2 (fr)	2024-03-09	2025-09-18	Aadigen, Llc	Compositions de traitement du cancer à mutations de kras et leurs utilisations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3404144A (en) *	1965-12-23	1968-10-01	Research Corp	1-beta-d-arabinofuranosyl-5-fluorocytosine compounds
GB1379410A (en) *	1971-06-08	1975-01-02	Upjohn Co	1-beta-d-arabino-furanosyl-n4-alpha-aminoacylcytosines
JPS52153977A (en) *	1976-06-11	1977-12-21	Daikin Ind Ltd	Synthesis of 5-fluorouracil and its derivatives
US4071680A (en) *	1976-12-20	1978-01-31	Hoffmann-La Roche Inc.	5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) *	1978-01-01	1982-12-31	Hoffmann La Roche	Novel nucleosides and process for their preparation
FR2528311B1 (fr) *	1982-06-14	1985-06-14	Synthelabo	Compositions pharmaceutiques a base de xylosides et lyxosides de bases puriques et pyrimidiques
JPS61112093A (ja) *	1984-11-05	1986-05-30	Wakunaga Seiyaku Kk	ヌクレオチド誘導体

1988
- 1988-11-02 CA CA000581964A patent/CA1327358C/fr not_active Expired - Lifetime
- 1988-11-07 EP EP88118515A patent/EP0316704B1/fr not_active Expired - Lifetime
- 1988-11-07 ES ES88118515T patent/ES2074429T3/es not_active Expired - Lifetime
- 1988-11-07 AT AT88118515T patent/ATE124951T1/de active
- 1988-11-07 DE DE2001199027 patent/DE10199027I2/de active Active
- 1988-11-07 DE DE3854148T patent/DE3854148D1/de not_active Expired - Lifetime
- 1988-11-08 US US07/268,437 patent/US4966891A/en not_active Expired - Lifetime
- 1988-11-10 NZ NZ226923A patent/NZ226923A/xx unknown
- 1988-11-10 ZA ZA888428A patent/ZA888428B/xx unknown
- 1988-11-10 YU YU209188A patent/YU47122B/sh unknown
- 1988-11-11 IL IL88363A patent/IL88363A0/xx not_active IP Right Cessation
- 1988-11-14 MC MC882015A patent/MC1992A1/fr unknown
- 1988-11-14 JP JP63285940A patent/JPH0678350B2/ja not_active Expired - Lifetime
- 1988-11-14 HU HU885799A patent/HU199866B/hu unknown
- 1988-11-15 KR KR1019880014983A patent/KR970000241B1/ko not_active Expired - Lifetime
- 1988-11-15 CS CS747588A patent/CS274486B2/cs not_active IP Right Cessation
- 1988-11-16 PH PH37820A patent/PH25641A/en unknown
- 1988-11-16 AR AR88312471A patent/AR247217A1/es active
- 1988-11-16 UA UA4356869A patent/UA19333A/uk unknown
- 1988-11-16 DZ DZ880179A patent/DZ1270A1/fr active
- 1988-11-16 DK DK640388A patent/DK170893B1/da not_active IP Right Cessation
- 1988-11-16 CN CN88107886A patent/CN1022688C/zh not_active Expired - Lifetime
- 1988-11-16 SU SU884356869A patent/SU1736342A3/ru active
- 1988-11-16 AU AU25168/88A patent/AU619220B2/en not_active Expired
- 1988-11-16 IE IE883430A patent/IE883430L/xx not_active IP Right Cessation
- 1988-11-16 PT PT89009A patent/PT89009B/pt not_active IP Right Cessation
- 1988-11-16 IS IS3412A patent/IS1895B/is unknown
- 1988-11-16 NO NO885106A patent/NO171167C/no not_active IP Right Cessation
- 1988-11-17 MX MX013836A patent/MX173347B/es unknown
- 1988-11-17 FI FI885329A patent/FI89804C/fi not_active IP Right Cessation
1993
- 1993-06-08 LV LV930507A patent/LV5624A3/xx unknown
- 1993-07-20 LT LTRP802A patent/LT2185B/xx not_active IP Right Cessation
1995
- 1995-10-10 GR GR950402791T patent/GR3017686T3/el unknown
2001
- 2001-05-02 LU LU90769C patent/LU90769I2/fr unknown
- 2001-05-17 NL NL300045C patent/NL300045I2/nl unknown
- 2001-07-17 NO NO2001013C patent/NO2001013I2/no unknown

Also Published As

Publication number	Publication date
IL88363A0 (en)	1989-06-30
SU1736342A3 (ru)	1992-05-23
EP0316704A2 (fr)	1989-05-24
NL300045I1 (nl)	2001-08-01
DE10199027I1 (de)	2001-08-02
ES2074429T3 (es)	1995-09-16
NL300045I2 (nl)	2002-01-02
FI885329A0 (fi)	1988-11-17
PT89009B (pt)	1993-02-26
IE883430L (en)	1989-05-17
HK1003114A1 (en)	1998-10-09
ZA888428B (en)	1989-06-28
PH25641A (en)	1991-08-21
DZ1270A1 (fr)	2004-09-13
DK640388D0 (da)	1988-11-16
NO171167C (no)	1993-02-03
DK640388A (da)	1989-05-18
DE3854148D1 (de)	1995-08-17
KR890008162A (ko)	1989-07-10
HUT48267A (en)	1989-05-29
HU199866B (en)	1990-03-28
PT89009A (pt)	1988-12-01
EP0316704B1 (fr)	1995-07-12
AU619220B2 (en)	1992-01-23
NO885106D0 (no)	1988-11-16
IS3412A7 (is)	1989-05-18
NO2001013I2 (no)	2006-05-01
FI89804C (fi)	1993-11-25
DE10199027I2 (de)	2002-01-31
FI89804B (fi)	1993-08-13
YU47122B (sh)	1994-12-28
NO885106L (no)	1989-05-18
CA1327358C (fr)	1994-03-01
CS274486B2 (en)	1991-04-11
LT2185B (lt)	1993-10-15
IS1895B (is)	2003-10-20
AU2516888A (en)	1989-05-25
CN1022688C (zh)	1993-11-10
NO171167B (no)	1992-10-26
YU209188A (en)	1990-08-31
NZ226923A (en)	1990-10-26
US4966891A (en)	1990-10-30
LV5624A3 (lv)	1994-05-10
MC1992A1 (fr)	1989-11-30
CN1033183A (zh)	1989-05-31
UA19333A (uk)	1997-12-25
DK170893B1 (da)	1996-03-04
ATE124951T1 (de)	1995-07-15
JPH01153696A (ja)	1989-06-15
AR247217A1 (es)	1994-11-30
EP0316704A3 (en)	1990-11-22
CS747588A2 (en)	1990-09-12
JPH0678350B2 (ja)	1994-10-05
MX173347B (es)	1994-01-03
GR3017686T3 (en)	1996-01-31
MX13836A (es)	1993-10-01
KR970000241B1 (ko)	1997-01-08
FI885329L (fi)	1989-05-18

Publication	Publication Date	Title
LU90829I2 (fr)	2001-11-12	Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
LU90219I2 (fr)	1998-05-28	Tolcapone et ses dérivés pharmaceutiquement acceptables (TASMAR)
LU91039I2 (fr)	2003-11-05	Proteq flu et ses dérivés pharmaceutiquement acceptables
LU90736I2 (fr)	2001-05-07	Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables
LU90069I2 (fr)	1997-07-23	Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip)
LU90484I2 (fr)	2000-02-21	Novorapid - insuline asparte et ses sels et derives pharmaceutiquement acceptables
LU91205I2 (fr)	2006-05-30	Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)
LU88736I2 (fr)	1996-08-23	Cefquinome et ses dérivés pharmaceutiquement acceptables (COBACTAN)
LU91197I2 (fr)	2005-10-31	Azoxystrobin et folpel et leurs dérivés pharmaceutiquement acceptables (QUADRIS MAX).
NO2001013I2 (no)	2006-05-01	Kapecitabin
LU88750I2 (fr)	1996-08-23	VENLAFAXINE et ses dérivés pharmaceutiquement acceptables
NZ227841A (en)	1991-08-27	Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
LU91147I2 (fr)	2005-05-17	Pemetrexed et ses sels pharmaceutiquement acceptables.
EP0237073A3 (en)	1989-11-15	Il-1alpha derivatives and drugs
LU88790I2 (fr)	1997-03-18	Moxidectin et ses dérivés pharmaceutiquement acceptables
NZ230144A (en)	1991-09-25	Phosphorus-substituted purine derivatives and pharmaceutical compositions
DK130389D0 (da)	1989-03-17	Catecholderivater og farmaceutiske praeparater omfatende samme
LU88843I2 (fr)	1997-03-14	Ropivacaine et ses dérivés pharmaceutiquement acceptables (Naropine R)
NO882462L (no)	1988-12-12	Fremstilling og bruk av fenolderivater.
FI922014A7 (fi)	1992-05-05	Nukleosidijohdannaiset
DK406689D0 (da)	1989-08-18	Terapeutiske nucleosider
NZ225613A (en)	1990-09-26	Benzazepin-2-one derivatives and pharmaceutical compositions
DK501288D0 (da)	1988-09-09	Orale magnesium- og kaliumpraeparater
NZ221350A (en)	1990-02-26	Uridine derivatives and pharmaceutical preparation
LU90110I2 (fr)	1997-09-25	Penciclovir et ses dérivés pharmaceutiquement acceptables